Lindagan, Sayba M.
HRN: 07-62-08 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/28/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/28/2025
10/28/2025
IV
350mg
Now
Septicemia Sec To CUTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes